Cdc7-IN-6

• CAT Number: I017550
• CAS Number: 1402057-88-8
• Molecular Formula: C₂₁H₂₂F₃N₅O₄
• Molecular Weight: 465.43
• Purity: ≥95%
• IUPAC Name: ethyl 4-hydroxy-5-[(Z)-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]-2-[[4-(2,2,2-trifluoroethyl)piperazin-1-yl]amino]furan-3-carboxylate
• InChI: InChI=1S/C21H22F3N5O4/c1-2-32-20(31)16-17(30)15(10-13-11-26-18-14(13)4-3-5-25-18)33-19(16)27-29-8-6-28(7-9-29)12-21(22,23)24/h3-5,10-11,27,30H,2,6-9,12H2,1H3/b13-10+
• InChIKey: HFBNZZVVRMLDJO-JLHYYAGUSA-N
• SMILES: CCOC(=O)C1=C(OC(=C1O)/C=C/2\C=NC3=C2C=CC=N3)NN4CCN(CC4)CC(F)(F)F

Cdc7-IN-6（Cat No.:I017550）is a selective inhibitor of cell division cycle 7 (Cdc7) kinase, an enzyme essential for initiating DNA replication by phosphorylating MCM helicase complexes. By inhibiting Cdc7, Cdc7-IN-6 blocks the progression of DNA synthesis, leading to replication stress and cell cycle arrest in rapidly dividing cells, particularly cancer cells. It has shown potential in preclinical studies for treating various cancers, including those resistant to traditional therapies. Cdc7-IN-6 is valuable for research into DNA replication control and is being explored for its therapeutic potential in oncology.

Reference

[1]. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.